# A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

> **NCT06593522** · PHASE2 · RECRUITING · sponsor: **Amgen** · enrollment: 200 (estimated)

## Conditions studied

- MTAP-deleted NSCLC

## Interventions

- **DRUG:** anvumetostat

## Key facts

- **NCT ID:** NCT06593522
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2028-11-29
- **Final completion:** 2030-11-29
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593522, "A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06593522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*